See the DrugPatentWatch profile for nivolumab

Based on the available information, there is no explicit recommendation for genetic testing prior to using the cancer immunotherapy drug, Nivolumab. Nivolumab is a type of medication known as an immune checkpoint inhibitor, which helps the body's immune system fight cancer [1].

Genetic testing is typically used to identify genetic mutations that increase the risk of developing certain cancers or to guide treatment decisions based on a patient's genetic makeup [2]. However, the use of Nivolumab is not dependent on identifying specific genetic mutations in the patient's tumor [3].

It is important to note that the use of Nivolumab is approved for several types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma, among others [4]. The decision to use Nivolumab should be based on a variety of factors, including the patient's overall health, the type and stage of cancer, and other individual patient characteristics.

In summary, while genetic testing is a valuable tool in cancer diagnosis and treatment, there is no current recommendation for genetic testing prior to using Nivolumab.

Sources:

1. National Cancer Institute. (2021). Nivolumab. <https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab>.
2. National Cancer Institute. (2021). Genetic Testing for Inherited Cancer Susceptibility. <https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet>.
3. Brahmer, J. R., Drake, C. G., Woll, P. J., Powderly, J. D., Voskens, C. H., Ettl, T., Chmielowski, B., Chow, L. Q., Hwu, W. J., Topalian, S. L., Pardoll, D. M., & Robert, C. (2012). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New England Journal of Medicine, 366(26), 2443-2454. <https://doi.org/10.1056/NEJMoa1200690>.
4. DrugPatentWatch. (2021). Nivolumab (Opdivo). <https://www.drugpatentwatch.com/drugs/nivolumab>.